⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Terlipressin

ترلیپرسین

⚠ Unverified

🧬 Systemic Hormonal Preparations, Excl. Sex Hormones And InsulinsVasopressin analogue

🤰 Pregnancy:Dangerous / avoid 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA022231 ATC H01BA04

Market / country: 🇺🇸 USA

Terlivaz (US)

🧮 Dose calculator

Disease / regimen

Hepatorenal syndrome · Regimen source: FDA Terlivaz · 2.2

• Day 4: continue if creatinine fell ≥30%; less: may increase per label chart (to 1.7 mg). Check SpO2 and ACLF grade first; continuous pulse oximetry. FDA Terlivaz · 2.2 FDA Terlivaz · 2.1 FDA Terlivaz · 2

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Hypoxia or worsening respiratory symptoms; ongoing coronary, peripheral or mesenteric ischaemia. FDA Terlivaz · 4

Warnings

• Boxed warning: serious or fatal respiratory failure (higher with volume overload or ACLF grade 3) — do not start or stop if SpO2 <90%. FDA Terlivaz · Boxed Warning
• Ischaemic events; ineligibility for liver transplant; embryo-fetal toxicity. FDA Terlivaz · 5

Formulations

0.85 mg vial — powder for injection 🇺🇸 USA FDA Terlivaz · 3

👥 Special populations

🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Terlivaz · 8.1
“Risk Summary Based on findings from the published literature and on its mechanism of action, TERLIVAZ may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] .”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Terlivaz · 8.2
“Risk Summary There are no data on the presence of terlipressin in human or animal milk, the effects on the breastfed infant, or the effect on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Terlivaz · 8.4
“Safety and effectiveness of TERLIVAZ have not been established in pediatric patients.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Terlivaz · 8.5
“Of the total number of patients in clinical studies treated with TERLIVAZ, 55 (16%) were ≥65 years of age.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA022231
DailyMed (FDA label)FDA Terlivaz
MedlinePlus (NIH)Terlipressin Injection
WHO ATC/DDDH01BA04
Darooyab (Iran)Terlipressin

🇮🇷 Not found in Iran list Darooyab · G-2721/Terlipressin

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Terlivaz · 3 FDA Terlivaz · 2.2 FDA Terlivaz · 2.1 FDA Terlivaz · 2 FDA Terlivaz · 4 FDA Terlivaz · Boxed Warning FDA Terlivaz · 5 FDA Terlivaz · 8.1 FDA Terlivaz · 8.2 FDA Terlivaz · 8.4 FDA Terlivaz · 8.5 FDA Terlivaz · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-2721/Terlipressin
Clinical review⚠ Unverified

🔗 Similar drugs

Same class

Desmopressin (tablet)